2009
Exactech Q3 Revenue $42.4M; Net Income $2.7M or $0.21 EPS
GAINESVILLE, Fla. – October 27, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that total revenue for the third quarter of 2009 increased 12% to $42.4 million from $37.9 million in the third quarter of 2008. Diluted earnings per share for the quarter was $0.21 based on net income of $2.7 million. This compares with net income of $2.1 million or $0.16 diluted EPS a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $845,000 related to the ongoing Department of Justice (DOJ) inquiry, was $3.3 million or $0.25 EPS.
Exactech Named As One Of America's 200 Best Small Companies by Forbes.com
Exactech, Inc. (Nasdaq: EXAC), has been Ranked #188 on the list of America's 200 Best Small Companies published by Forbes.com.
Exactech to Present at the 2009 Noble Financial Equity Conference on June 8
GAINESVILLE, Fla. -- June 1, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at the Fifth Annual Noble Financial Equity Conference in Hollywood, Florida. The two-day investor conference will showcase 140 small cap public companies.
Exactech Q1 Revenue Increases 9% to $43.3 Million
GAINESVILLE, Fla. -- April 29, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $43.3 million for the first quarter of 2009, a 9% increase over $39.8 million in the first quarter of 2008. Net income was $2.5 million, or $0.19 per diluted share, compared to $2.8 million, or $0.23 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $1.4 million related to the ongoing Department of Justice (DOJ) inquiry, was $3.3 million or $0.26 EPS.
Exactech Schedules First Quarter 2009 Earnings Release and Conference Call
GAINESVILLE, Fla. -- April 23, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter financial results on Wednesday, April 29, 2009 after regular trading hours end. A copy of the earnings release will be available at http://www.hawkassociates.com.
Exactech 2008 Revenue Up 30% to $162M; Net Income Up 31% to $11.1M, EPS $0.87
GAINESVILLE, Fla. -- February 18, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that revenue for 2008 increased 30% to $161.7 million from $124.2 million in 2007. Diluted earnings per share for the year was $0.87 based on net income of $11.1 million. This compares with net income of $8.5 million or $0.72 diluted EPS a year ago. Net income for 2008 included pre-tax legal expenses and costs of $2.6 million related to the ongoing Department of Justice (DOJ) inquiry.
Exactech, Inc. Announces Year End Earnings and Conference Call
GAINESVILLE, Fla. -- Feb. 12, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its fourth quarter and 2008 year-end earnings on Wednesday, February 18, 2009, after the market closes.
